Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Multiple Sclerosis

Free Subscription 06.04.2026 1 BMC Neurol 1 Can J Neurol Sci 3 J Neurol 5 J Neurol Sci 5 Mult Scler 1 Neurology 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. SONG Y, Zhao H, Wu Q, Xie S, et al
   Association of the along?perivascular space (ALPS) index and white matter volume with cognitive dysfunction in relapsing?remitting multiple sclerosis patients.
   BMC Neurol. 2026 Mar 27. doi: 10.1186/s12883-026-04826.
   PubMed        
   
   

   
   Can J Neurol Sci

2. NATHOO N
   Reviewer Comment on Zubkow et al. "Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis".
   Can J Neurol Sci. 2026 Mar 27:1. doi: 10.1017/cjn.2026.10537.
   PubMed        
   
   

   
   J Neurol

3. NERI F, Bianchi A, Luchetti L, Breccia D, et al
   Functional head impulse testing for detection and quantification of vestibular dysfunction in multiple sclerosis.
   J Neurol. 2026;273:245.
   PubMed         Abstract available
   
   
4. HAYES MTG, Beadnall HN, Merlo D, Monif M, et al
   Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.
   J Neurol. 2026;273:243.
   PubMed         Abstract available
   
   
5. GUO J, Olsson T, Johansson E, Alfredsson L, et al
   Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.
   J Neurol. 2026;273:240.
   PubMed         Abstract available
   
   

   
   J Neurol Sci

6. BAHARUDDIN B, Febriza A, Handayani L, Akl MM, et al
   Comments on: "Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in individuals with multiple sclerosis (iwMS)".
   J Neurol Sci. 2026;485:125901.
   PubMed        
   
   
7. SUKUMAR M, Annadurai K
   Comment on "Cost-effectiveness analysis of high-efficacy drugs used in the treatment of multiple sclerosis in a large health insurance provider in Brazil".
   J Neurol Sci. 2026;485:125884.
   PubMed        
   
   
8. SCHUMACHER FL, Cutter G, Burd CE, Archer K, et al
   Clocks out of sync: Increased epigenetic aging variability in multiple sclerosis.
   J Neurol Sci. 2026;485:125904.
   PubMed         Abstract available
   
   
9. PETRACCA M, Cocozza S, Cuocolo R
   Response to letter to the editor: Authors response to comment on "Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features".
   J Neurol Sci. 2026 Mar 27:125887. doi: 10.1016/j.jns.2026.125887.
   PubMed        
   
   
10. MOKKAPATI A, Thakkar R, Rani A, Puri D, et al
    Comment on "Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features".
    J Neurol Sci. 2026 Mar 25:125888. doi: 10.1016/j.jns.2026.125888.
    PubMed        
    
    

    
    Mult Scler

11. ANDERSEN ML, Anru PL, Sorensen E, Jolving LR, et al
    Treatment-requiring postpartum depression in mothers with multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2026 Apr 3:13524585261429255. doi: 10.1177/13524585261429255.
    PubMed         Abstract available
    
    
12. CAMPAGNA MP, Bove R
    Menopause is a progression event in multiple sclerosis: Yes.
    Mult Scler. 2026 Apr 1:13524585261429827. doi: 10.1177/13524585261429827.
    PubMed        
    
    
13. BACCHETTI A, McCormack B, Lin TY, Filippatou AG, et al
    Influence of OSCAR-IB criteria on test-retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis.
    Mult Scler. 2026 Mar 29:13524585261426768. doi: 10.1177/13524585261426768.
    PubMed         Abstract available
    
    
14. STRIJBIS E, Mostert J, D'Haeseleer M, Moral E, et al
    Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.
    Mult Scler. 2026;32:429-439.
    PubMed         Abstract available
    
    
15. GIOVANNONI G
    Immunological and other multiple sclerosis prodromes.
    Mult Scler. 2026;32:355-358.
    PubMed        
    
    

    
    Neurology

16. TOURNIER A, Gavoille A, Pique J, Levraut M, et al
    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
    Neurology. 2026;106:e214806.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

17. MOCCIA M, Cocozza S
    Contribution of new imaging sequences to the diagnosis of multiple sclerosis.
    Rev Neurol (Paris). 2026 Apr 1:S0035-3787(26)00464.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum